Monitor for future updates on sales traction, cGMP approval timeline, and additional product launches. The absence of financials limits near-term trading impact, but successful commercialization could support recurring revenue growth in 2026–2027.
Price Chart
Executive Summary
Dyadic International and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free), the first product from their expanded collaboration. This marks a step toward commercializing Dyadic's microbial expression platform, with additional recombinant proteins planned for 2026 in high-growth biomanufacturing and cell therapy applications.
Key Facts
- Dyadic and Fermbox Bio launched Recombinant DNase I (RNase-free), the first commercial product under their expanded 2025 collaboration.
- Product is currently available in research grade; cGMP-grade version is in development for biopharmaceutical and cell/gene therapy use.
- Dyadic provides its fungal expression platforms and strains; Fermbox handles downstream processing, scale-up, and manufacturing.
- Pipeline includes recombinant α-lactalbumin, transferrin, human FGF-2, and lactoferrin, targeting cell culture media and molecular biology reagents.
- No financial figures (pricing, revenue, deal value) were disclosed in the release.
Financial Impact
No financial impact can be estimated at this time — no pricing, volume, or revenue figures disclosed.
Risk Factors
- No guarantee of market adoption or regulatory acceptance of cGMP-grade products.
- Dyadic has a history of net losses and depends on third-party collaborations for revenue.
- Forward-looking statements are subject to significant risks including funding needs and competition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | SC 13G | $0.4194 | awaiting T+20 | — | $0.4046 (−3.53%) |
Sep 25, 2026 4w ago | 8-K | $0.4650 $0.4160 | ▲ +10.54% | ▲ +10.51% | $0.4046 (+12.99%) |
Sep 21, 2026 5w ago | EFFECT | $0.4010 $0.3809 | ▲ +5.01% | ▲ +4.10% | $0.4046 (−0.90%) |
Aug 14, 2026 10w ago | 8-K | $0.7751 $0.4244 | ▲ +45.25% | ▲ +43.25% | $0.4046 (+47.80%) |
Aug 12, 2026 10w ago | 8-K | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.4046 (+54.02%) |
Aug 12, 2026 10w ago | Press Release | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.4046 (+54.02%) |
Jul 24, 2026 13w ago | 8-K | $1.19 $0.6900 | ▼ −42.02% | ▼ −45.64% | $0.4046 (−66.00%) |
Jun 18, 2026 18w ago | DEFA14A | $0.7820 $1.19 | ▼ −52.17% | ▼ −51.64% | $0.4046 (+48.26%) |
May 28, 2026 21w ago | 8-K | $0.7100 $0.8010 | ▲ +12.82% | ▲ +15.96% | $0.4046 (−43.01%) |
Mar 25, 2026 30w ago | Press Release | $0.7000 $0.8600 | ▲ +22.86% | ▲ +12.19% | $0.4046 (−42.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers